Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard
treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously
untreated for metastatic PDA, including subjects who have received prior neoadjuvant or
adjuvant treatment.